CTS 3157
Alternative Names: CTS-3157Latest Information Update: 31 May 2023
At a glance
- Originator CytosinLab Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours